These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. Antisense applications for biological control. Pan WH; Clawson GA J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307 [TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT; Parkinson DR Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689 [TBL] [Abstract][Full Text] [Related]
5. Making sense of antisense. Vidal L; Blagden S; Attard G; de Bono J Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851 [TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides: from design to therapeutic application. Chan JH; Lim S; Wong WS Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890 [TBL] [Abstract][Full Text] [Related]
8. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides. Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362 [TBL] [Abstract][Full Text] [Related]